{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:48:42Z","timestamp":1782906522923,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1124\/dmd.114.058784","type":"journal-article","created":{"date-parts":[[2014,8,9]],"date-time":"2014-08-09T04:12:28Z","timestamp":1407557548000},"page":"1780-1784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1"],"prefix":"10.1016","volume":"42","author":[{"given":"J. William","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej J.","family":"Zamek-Gliszczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.058784_bib1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.058784_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.114.058784_bib3","first-page":"307","article-title":"Cloning and functional characterization of the multidrug resistance-associated protein (MRP1\/ABCC1) from the cynomolgus monkey","volume":"2","author":"Godinot","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.114.058784_bib4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.112.050732","article-title":"Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole","volume":"41","author":"Han","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/dmd.112.044875","article-title":"Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics","volume":"40","author":"Higgins","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.113.052290","article-title":"Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17\u03b2-glucuronide, estrone-3-sulfate, and sulfobromophthalein","volume":"41","author":"Izumi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib9","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.114.058784_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","article-title":"Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies","volume":"95","author":"Ke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-3565(24)35228-0","article-title":"Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity","volume":"291","author":"Kim","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.058784_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/bdd.1832","article-title":"Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs","volume":"34","author":"Liu","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.058784_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bcp.12177","article-title":"Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers","volume":"77","author":"Markert","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.058784_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1124\/dmd.106.009530","article-title":"Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells","volume":"34","author":"Sai","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.114.058784_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2010.119","article-title":"Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data","volume":"88","author":"Templeton","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib20","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1124\/dmd.111.040477","article-title":"Kinetic characterization of rat hepatic uptake of 16 actively transported drugs","volume":"39","author":"Yabe","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.058784_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2013.45","article-title":"ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans","volume":"94","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.058784_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","article-title":"Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study","volume":"49","author":"Zhao","year":"2009","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.058784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:37:21Z","timestamp":1739907441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0090955624115085"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.058784","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.058784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}